MoonLake Immunotherapeutics
Price Action
Technical Summary
EMERGING TRENDMoonLake Immunotherapeutics is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 88), indicating clear outperformance against the broad market. Earnings contraction of 56% provides fundamental context to the price action. Investors should exercise caution due to high volatility (116% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $19.02 | +4.65% | ABOVE |
| 50 SMA | $18.11 | +9.90% | ABOVE |
| 100 SMA | $17.70 | +12.42% | ABOVE |
| 150 SMA | $16.64 | +19.60% | ABOVE |
| 200 SMA | $17.85 | +11.48% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is MLTX in an uptrend right now?
MLTX has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is MLTX overbought or oversold?
MLTX's RSI (14) is 57. The stock is in neutral territory, neither overbought nor oversold.
Is MLTX outperforming the market?
MLTX has a Relative Strength (RS) Rating of 88 out of 99. Yes, MLTX is a market leader, outperforming 88% of all stocks over the past 12 months.
Where is MLTX in its 52-week range?
MLTX is trading at $19.90, which is 32% of its 52-week high ($62.75) and 25% above its 52-week low ($5.95).
How volatile is MLTX?
MLTX has a Beta of 1.19 and 52-week volatility of 116%. It's more volatile than the S&P 500 - expect bigger swings.